WILLIAM T. SHARP
Co-founder, Chief Executive Officer & Director
With more than thirty years of executive, general management, business development, sales, marketing, and technology commercialization experience, Mr. Sharp’s career spans private venture-backed businesses, mid-size and Fortune 100 public companies in the medical device, diagnostics and life science tools and services markets. Mr. Sharp has served in senior leadership roles with five venture-backed companies—as Chief Executive Officer of CYTOO, Inc. and ArunA Biomedical, Chief Commercial Officer of BioProcessors Corporation (acquired by Seahorse Biosciences), SVP Business Development of Cellomics (acquired by Fisher International), and VP Business Development of Gentra Systems (acquired by Qiagen). Earlier career includes senior leadership roles with Life Technologies, General Manager of Terumo Medical, Vice President of Sales and Marketing at Heraeus Instruments and roles of increasing responsibility within the diagnostics business of Baxter Healthcare and a medical device subsidiary of Eli Lilly. Mr. Sharp has successfully commercialized more than 500 products and services. Earned M.S. and B.A. degrees from the Pennsylvania State University.
Chief Operating Officer
Bringing over 25 years of experience in the pharmaceutical, biomedical and biotechnology industries to DxNow, Mr. Sly has global responsibility for marketing, regulatory, manufacturing and overall business operations. Prior to joining the DxNow team, Mr. Sly directed the commercial strategy, marketing and business development activities for Baltimore-based Paragon Bioservices. Throughout his career, Mr. Sly’s focus has primarily been strategic marketing and business development, from leading the efforts in pharmaceutical technology licensing and product development (including Phase I–III development and commercial manufacturing), to the development of business strategy and strategic commercial development for a range of biopharmaceutical products. Mr. Sly joined the Maryland business community in 2002 as Chief Business Officer for a private start-up, Advancis Pharmaceutical Corporation, playing a critical role in establishing a strong marketing presence, delivering key validating licensing and acquisition deals, serving on the core IPO deal team and leading the post-IPO efforts to establish the company’s first commercial operations. He received his B.A. in Biology (pre-med) from Pomona College.
Vice President, Business Development
Mr. Rau’s career extends over three decades in sales, sales management, business development, basic research and product development. His responsibilities for DxNow are currently focused on developing our global business efforts in veterinary fertility and our human fertility distribution network in the Asia-Pacific region. Mr. Rau’s experience spans venture-backed businesses, mid-size and Fortune 500 public companies in the medical device, diagnostics and life science tools and services markets. Mr. Rau’s venture-backed experience includes his most recent role as Director of Business Development for Spartan Bioscience in which he successfully established global distribution channels plus engaged in the initiation and direction of collaborative partnerships. Previous business development, sales, and sales management experience includes fourteen years with Gentra Systems (acquired by Qiagen) where he held all sales records, Sequenom, and Pall Corporation. During his early career, Mr. Rau gained basic research and product development experience at Kallestad (now owned by Danaher – Beckman Coulter), the University of Wisconsin and the University of Minnesota. Mr. Rau earned his B.S. degree from the University of Wisconsin-Madison.
JEFFREY SCOTT SHIPPY
Interim Chief Financial Officer
Mr. Shippy has more than 25 years of experience advising MedTech, diversified healthcare, and other companies. He has served in a strategic finance role for companies at all stages of their lifecycles, from start-up to exit, including on an Interim CFO basis. Mr. Shippy’s background includes not only public accounting and corporate finance, but also strategy consulting and investment banking. In addition to serving as Interim CFO for DxNow and ZyMōt Fertility, Mr. Shippy is the Founder and CEO of Audacity Investment Bankers, a boutique investment bank and management consulting firm that is dedicated to serving MedTech companies of all types, including FDA-approved medical device companies and contract manufacturers. Prior to founding Audacity, Mr. Shippy was a Partner and Director of Healthcare at Stout Investment Bank, one of the nation’s fastest growing middle-market investment banks. Prior to Stout, he served as an investment banker at Houlihan Lokey (NYSE: HLI), one of the nation’s largest Wall Street investment banks. Prior to investment banking, he was a strategy consultant at Accenture (NYSE:ACN) in Palo Alto, California. Mr. Shippy also worked at Epic Ventures, a former Draper Fisher Jurvetson affiliate and early-stage venture capital firm with a focus on investing in early-stage biotech and other disruptive technology ventures. He began his career as a licensed C.P.A. at a major global public accounting firm. Mr. Shippy holds an M.B.A. in International Finance from Thunderbird, and a B.S. in Accountancy from Northern Illinois University.